Latest news
PRESSRELEASE New patent for ICOone
PRESSRELEASE 230126:
The European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication…
Iconovo i Penserpodden
Penserpodden är en podd om aktier, börs och marknad där några av våra mest framstående förvaltare och analytiker går igenom allt från både…
Press releases
Feb 08, 2023, 17:32
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 03, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 03, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Jan 11, 2023, 08:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se